BRISTOL-MYERS SQUIBB CO (BMY) Stock Fundamental Analysis

NYSE:BMY • US1101221083

61.075 USD
-0.22 (-0.37%)
Last: Feb 26, 2026, 03:49 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to BMY. BMY was compared to 192 industry peers in the Pharmaceuticals industry. While BMY has a great profitability rating, there are some minor concerns on its financial health. BMY is valued quite cheap, but it does not seem to be growing. BMY also has an excellent dividend rating. These ratings could make BMY a good candidate for value and dividend investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year BMY was profitable.
  • BMY had a positive operating cash flow in the past year.
  • Of the past 5 years BMY 4 years were profitable.
  • Each year in the past 5 years BMY had a positive operating cash flow.
BMY Yearly Net Income VS EBIT VS OCF VS FCFBMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • BMY's Return On Assets of 7.83% is amongst the best of the industry. BMY outperforms 89.06% of its industry peers.
  • BMY's Return On Equity of 38.19% is amongst the best of the industry. BMY outperforms 96.88% of its industry peers.
  • The Return On Invested Capital of BMY (19.52%) is better than 96.35% of its industry peers.
  • BMY had an Average Return On Invested Capital over the past 3 years of 14.47%. This is in line with the industry average of 12.96%.
  • The last Return On Invested Capital (19.52%) for BMY is above the 3 year average (14.47%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROIC 19.52%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
BMY Yearly ROA, ROE, ROICBMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • BMY has a Profit Margin of 14.64%. This is amongst the best in the industry. BMY outperforms 86.46% of its industry peers.
  • In the last couple of years the Profit Margin of BMY has grown nicely.
  • BMY's Operating Margin of 35.82% is amongst the best of the industry. BMY outperforms 95.83% of its industry peers.
  • In the last couple of years the Operating Margin of BMY has grown nicely.
  • BMY has a better Gross Margin (72.63%) than 80.73% of its industry peers.
  • In the last couple of years the Gross Margin of BMY has remained more or less at the same level.
Industry RankSector Rank
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
BMY Yearly Profit, Operating, Gross MarginsBMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMY is creating value.
  • The number of shares outstanding for BMY has been increased compared to 1 year ago.
  • Compared to 5 years ago, BMY has less shares outstanding
  • Compared to 1 year ago, BMY has an improved debt to assets ratio.
BMY Yearly Shares OutstandingBMY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
BMY Yearly Total Debt VS Total AssetsBMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • BMY has an Altman-Z score of 2.56. This is not the best score and indicates that BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BMY (2.56) is better than 67.19% of its industry peers.
  • BMY has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as BMY would need 3.51 years to pay back of all of its debts.
  • BMY has a better Debt to FCF ratio (3.51) than 88.54% of its industry peers.
  • A Debt/Equity ratio of 2.33 is on the high side and indicates that BMY has dependencies on debt financing.
  • With a Debt to Equity ratio value of 2.33, BMY is not doing good in the industry: 78.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Altman-Z 2.56
ROIC/WACC2.24
WACC8.7%
BMY Yearly LT Debt VS Equity VS FCFBMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B 50B

2.3 Liquidity

  • A Current Ratio of 1.26 indicates that BMY should not have too much problems paying its short term obligations.
  • BMY has a worse Current ratio (1.26) than 77.08% of its industry peers.
  • BMY has a Quick Ratio of 1.14. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
  • BMY has a worse Quick ratio (1.14) than 74.48% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.14
BMY Yearly Current Assets VS Current LiabilitesBMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • The Earnings Per Share has been decreasing by -0.92% on average over the past years.
  • Looking at the last year, BMY shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
  • Measured over the past years, BMY shows a small growth in Revenue. The Revenue has been growing by 2.54% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.54% on average over the next years.
  • Based on estimates for the next years, BMY will show a decrease in Revenue. The Revenue will decrease by -5.62% on average per year.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-1.88%
Revenue Next 2Y-2.07%
Revenue Next 3Y-5.43%
Revenue Next 5Y-5.62%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BMY Yearly Revenue VS EstimatesBMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BMY Yearly EPS VS EstimatesBMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

8

4. Valuation

4.1 Price/Earnings Ratio

  • BMY is valuated reasonably with a Price/Earnings ratio of 9.93.
  • 92.71% of the companies in the same industry are more expensive than BMY, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of BMY to the average of the S&P500 Index (27.05), we can say BMY is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 10.04, the valuation of BMY can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, BMY is valued cheaper than 88.54% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of BMY to the average of the S&P500 Index (28.03), we can say BMY is valued rather cheaply.
Industry RankSector Rank
PE 9.93
Fwd PE 10.04
BMY Price Earnings VS Forward Price EarningsBMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BMY is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMY indicates a rather cheap valuation: BMY is cheaper than 91.67% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.68
EV/EBITDA 7.45
BMY Per share dataBMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The excellent profitability rating of BMY may justify a higher PE ratio.
  • A cheap valuation may be justified as BMY's earnings are expected to decrease with -3.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%

7

5. Dividend

5.1 Amount

  • BMY has a Yearly Dividend Yield of 4.18%, which is a nice return.
  • Compared to an average industry Dividend Yield of 1.07, BMY pays a better dividend. On top of this BMY pays more dividend than 96.88% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, BMY pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.18%

5.2 History

  • On average, the dividend of BMY grows each year by 6.51%, which is quite nice.
  • BMY has paid a dividend for at least 10 years, which is a reliable track record.
  • BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)6.51%
Div Incr Years3
Div Non Decr Years3
BMY Yearly Dividends per shareBMY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • BMY pays out 71.52% of its income as dividend. This is not a sustainable payout ratio.
  • The Dividend Rate of BMY has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
BMY Yearly Income VS Free CF VS DividendBMY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
BMY Dividend Payout.BMY Dividend Payout, showing the Payout Ratio.BMY Dividend Payout.PayoutRetained Earnings

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (2/26/2026, 3:49:07 PM)

61.075

-0.22 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners81.87%
Inst Owner Change0.41%
Ins Owners0.02%
Ins Owner Change-1.12%
Market Cap124.33B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.59
Price Target58.05 (-4.95%)
Short Float %1.47%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield 4.18%
Yearly Dividend2.51
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years3
Div Non Decr Years3
Ex-Date01-02
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)2.01%
PT rev (3m)9.49%
EPS NQ rev (1m)1.98%
EPS NQ rev (3m)-3.3%
EPS NY rev (1m)0.24%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)3.43%
Revenue NQ rev (3m)3.33%
Revenue NY rev (1m)6.84%
Revenue NY rev (3m)7.45%
Valuation
Industry RankSector Rank
PE 9.93
Fwd PE 10.04
P/S 2.58
P/FCF 9.68
P/OCF 8.78
P/B 6.73
P/tB N/A
EV/EBITDA 7.45
EPS(TTM)6.15
EY10.07%
EPS(NY)6.09
Fwd EY9.96%
FCF(TTM)6.31
FCFY10.33%
OCF(TTM)6.95
OCFY11.39%
SpS23.67
BVpS9.07
TBVpS-11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.44
Profitability
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROCE 25.91%
ROIC 19.52%
ROICexc 23.22%
ROICexgc 84.94%
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
FCFM 26.65%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Debt/EBITDA 2.03
Cap/Depr 32.69%
Cap/Sales 2.72%
Interest Coverage 8.22
Cash Conversion 66.54%
Profit Quality 182.1%
Current Ratio 1.26
Quick Ratio 1.14
Altman-Z 2.56
F-Score7
WACC8.7%
ROIC/WACC2.24
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.88%
Revenue Next 2Y-2.07%
Revenue Next 3Y-5.43%
Revenue Next 5Y-5.62%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%

BRISTOL-MYERS SQUIBB CO / BMY FAQ

What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BMY.


What is the valuation status for BMY stock?

ChartMill assigns a valuation rating of 8 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.


What is the profitability of BMY stock?

BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 9 / 10.


Can you provide the financial health for BMY stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (BMY) is 5 / 10.


What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BMY) stock?

The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to decline by -1.05% in the next year.